Interest in Beckman Coulter (BEC.N) from strategic bidders is waning as a recent runup in the medical testing company's stock threatens to drive away price sensitive buyers, several sources familiar with the situation said on Friday. That could give the advantage to private equity firms, which have been pairing up to bid for the company, valued at $5.1 billion according to Friday's closing share price. Beckman's shares fell 2.1 percent to close at $74.41.
Source
